Morepen Laboratories expands diabetes treatment access with affordable Empamore launch
Morepen Laboratories Limited has taken a major step in diabetes treatment with the launch of Empamore diabetes treatment, a cost-effective alternative aimed at providing broader ... Read More
Alkem Laboratories’ latest drug launch promises relief for millions of diabetics in India
Alkem Laboratories Limited has launched its generic version of empagliflozin and its combinations in India under the brand name Empanorm, offering a significant price reduction ... Read More
Glenmark Pharmaceuticals expands cardiometabolic portfolio with new Empagliflozin drug launch
Glenmark Pharmaceuticals Ltd. has introduced Empagliflozin, a widely recognized SGLT2 inhibitor, in India under the brand name Glempa. Along with this, the company has launched ... Read More
Boehringer Ingelheim’s BI 690517 shows up to 39.5% albuminuria reduction in Phase II trial
Boehringer Ingelheim has revealed promising results from its 14-week Phase II trial for BI 690517, a novel selective aldosterone synthase inhibitor. The data highlights a ... Read More